Francis deSouza resigned from gene-sequencing maker after regulators challenged $7.1 billion deal, triggering proxy battle with Carl Icahn.
Francis deSouza resigned from gene-sequencing maker after regulators challenged $7.1 billion deal, triggering proxy battle with Carl Icahn.